C-Path shares similar objectives (the accelerated development of safer, more effective therapies) with the Innovative Medicines Initiative (IMI): a PPP between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA) founded in 2007 and based in Brussels. Both C-Path and IMI bring together scientists from the pharmaceutical industry and academic institutions, as well as representatives from patient organizations and regulatory agencies, to form pre-competitive PPPs that address scientific challenges impeding the successful development of new medical products.
In June 2011, C-Path and IMI signed an MoU indicating the intent of the two organizations to find opportunities to leverage one another’s work to accelerate progress and prevent duplication of efforts. The collaboration fosters increased information sharing between each organization’s programs, facilitating knowledge exchange and scientific consensus for research and testing methods. It also establishes a platform for data oversight and management, so non-competitive information can be made available for public use.